LEAP-2 (Liver-expressed antimicrobial peptide 2) has been characterized as an endogenous competitive antagonist of ghrelin and proposed as a potential therapeutic target for obesity (128, 129). Here, LEAP2 is linked to obesity due to melanocortin 4 receptor deficiency.